PHOTO ADVISORY -- EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relap

Editors are advised that high-resolution photos are available to accompany the news release, SF07905, EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis, issued earlier today by EMD Serono, Inc.

Caption-a: EMD Serono Logo 1

Caption-b: EMD Serono Logo 2 ... (PRNewsFoto)

Members of the media may download the photos at no charge from the following online archives:

-- PR Newswire Photo Archive: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-a

-- PR Newswire Photo Archive: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-b

For more information on the photos, or on gaining access to the archives, media may contact the PR Newswire Photo Desk at [email protected] .

/PRNewswire -- 11/26/2010/

SOURCE EMD Serono, Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.